Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Gabrail Cancer Center Research
- Target Recruit Count
- 14
- Registration Number
- NCT02250885
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- GSO Global Clinical Research BV
- Target Recruit Count
- 42
- Registration Number
- NCT02249091
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 244
- Registration Number
- NCT02227251
- Locations
- 🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Virginia Mason Hospital & Medical Center, Seattle, Washington, United States
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 14
- Registration Number
- NCT02215161
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02212561
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 100
- Registration Number
- NCT02199665
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸Mayo Clinic (AZ), Scottsdale, Arizona, United States
🇺🇸Wayne State University Karmanos Cancer Institute, Detroit, Michigan, United States
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2023-01-04
- Target Recruit Count
- 28
- Registration Number
- NCT02186834
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Mohammed Najeeb Al Hallak
- Target Recruit Count
- 15
- Registration Number
- NCT02178436
- Locations
- 🇺🇸
Stony Brook University Cancer Center, Stony Brook, New York, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 20
- Registration Number
- NCT02146833
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 27
- Registration Number
- NCT02138786
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇩🇪University of Ulm, Ulm, Baden-Württemberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.